mCRPC Patient Identification

Identifying appropriate patients for PLUVICTO is more important than ever. AIM for PLUVICTO even earlier for your patients with PSMA+ mCRPC.^1,2

After your patients with PSMA+ mCRPC receive their first ARPI, be ready for what's next.¹ Be ready to rethink the sequence.*

*For patients considered appropriate to delay taxane-based chemotherapy.¹

Identifying Patients

AIM for PLUVICTO even earlier in mCRPC^1,2

AIM for Pluvicto even earlier in mCRPC. AIM: After only 1 ARPI, Imaging confirms PSMA+ disease, Metastatic CRPC

1 ARPI could have been received at any point in your patient’s prostate cancer journey, including in the castration-sensitive setting^1,2

ARPI, androgen receptor pathway inhibitor; CRPC, castration-resistant prostate cancer; mAPMR PC, metastatic androgen pathway modulation-resistant prostate cancer; mCRPC, metastatic castration-resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive.

Patient Profiles

Meet patients with PSMA+ mCRPC who are eligible for PLUVICTO

Plan for PLUVICTO after only 1 ARPI, which could have been received at any point in your patient’s journey^1,2

Robert, 68

Received 1 ARPI in the mHSPC setting

Localized prostate cancer: Radical prostatectomy
- 4 years
BCR occurred (nmHSPC): Monitoring for 12 months
mCRPC: ADT + ARPI for 21 months
PSA began to rise: Diagnosed with PSMA+ mCRPC

Has bone and lymph node metastases with asymptomatic disease

James, 70

Received 1 ARPI in the mCRPC setting

Localized prostate cancer: EBRT
- 2 years
BCR occurred (nmHSPC): ADT for 2 years
mCRPC: ADT + ARPI for 11 months
PSA began to rise: PSMA-PET shows positive disease

Has bone and lymph node metastases with mildly symptomatic disease

Hypothetical patient cases.

ADT, androgen deprivation therapy; BCR, biochemical recurrence; EBRT, external beam radiation therapy; mHSPC, metastatic hormone-sensitive prostate cancer; nmHSPC, nonmetastatic hormone-sensitive prostate cancer; PET, positron emission tomography; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen.

Advancing PLUVICTO Therapy for the Right Patients

Glen Gejerman, MD, MBA, reviews what PLUVICTO therapy is at a live event, summarizing PLUVICTO data, presenting a hypothetical case of a patient with PSMA+ mAPMR prostate cancer (mCRPC), and highlighting what types of patients are eligible for PLUVICTO.

Care Team Perspectives for a Patient With Metastatic APMN/S Prostate Cancer (mHSPC) Who Received an ARPI and Recently Progressed to Metastatic APMR Prostate Cancer (mCRPC)

Nuclear medicine physician Dr Phillip Koo, medical oncologist Dr Scott Tagawa, and urologist Dr Jason Hafron review a case of a patient previously treated with an ARPI for mAPMN/S prostate cancer (mHSPC) who progressed to mAPMR prostate cancer (mCRPC).

Planning Ahead for PLUVICTO for Patients With Metastatic APMR Prostate Cancer (mCRPC)

Urologist Jose De La Cerda, MD, provides insights about the importance of aggressive treatment for patients with advanced prostate cancer as well as considerations about planning for PLUVICTO.

Identifying Progression in Patients With Metastatic APMR Prostate Cancer (mCRPC) to Plan Ahead for PLUVICTO

Urologist Scott Sellinger, MD, provides insights about the importance of progression and guideline-aligned therapy options in advanced prostate cancer after an ARPI, including the importance of presenting PLUVICTO as a therapy option at first eligibility.

Optimizing Treatment in Metastatic APMR Prostate Cancer (mCRPC) Beyond ARPI

Medical oncologist Bradley Somer, MD, shares insights on optimizing treatment in advanced prostate cancer beyond ARPI therapy, highlighting the need for continued education on logistics and key stakeholders to build HCP comfort with PLUVICTO.

Acting Early for Patients With Metastatic APMR Prostate Cancer (mCRPC)

Learn from Aaron Berger, MD, about the need for aggressive therapy when treating mAPMR prostate cancer (also known as mCRPC) and PLUVICTO as an option.

The Health Care Professionals in these videos have been compensated for their time by Novartis Pharmaceuticals Corporation.

Plan for PLUVICTO

For patients with PSMA+ mCRPC progressing on 1 ARPI

PLAN EARLY FOR PLUVICTO INITIATION

When PSA rises, your patient on an ARPI may worry that his cancer has progressed. But you have an answer: Let's make a plan for PLUVICTO initiation after confirmed progression.^1,3

PLAN
at 1st PSA rise

Discuss potential biomarker-driven therapy such as PLUVICTO, a PSMA-targeted therapy¹
Schedule and complete prior authorization for PSMA-PET scan

SCAN
for PSMA at confirmed PSA rise*

Confirm PSMA+ status to establish PLUVICTO eligibility¹
Locate PLUVICTO Treatment Centers

REFER
at PSMA+ mCRPC

At confirmed PSMA+ mCRPC after only 1 ARPI, refer the patient to a designated treatment center
Novartis Patient Support™ can help you understand patient coverage and affordability and provide your patients with 1:1 support

*2 increases in PSA measured at least 1 week apart is considered a sign of progression for inclusion criterion in the PSMAfore clinical trial.⁴

Find a treatment center Learn more about Novartis Patient Support

Which of your patients with PSMA+ mCRPC could benefit from PLUVICTO now?

See mCRPC trial data

< Previous: mCRPC Overview

Next: Efficacy After Only 1 ARPI >

After your patients with PSMA+ mCRPC receive their first ARPI, be ready for what's next.¹ Be ready to rethink the sequence.*

Meet patients with PSMA+ mCRPC who are eligible for PLUVICTO

Plan for PLUVICTO after only 1 ARPI, which could have been received at any point in your patient’s journey^1,2